JP2013515490A5 - - Google Patents

Download PDF

Info

Publication number
JP2013515490A5
JP2013515490A5 JP2012546239A JP2012546239A JP2013515490A5 JP 2013515490 A5 JP2013515490 A5 JP 2013515490A5 JP 2012546239 A JP2012546239 A JP 2012546239A JP 2012546239 A JP2012546239 A JP 2012546239A JP 2013515490 A5 JP2013515490 A5 JP 2013515490A5
Authority
JP
Japan
Prior art keywords
lactic acid
composition
acid bacterium
antigen
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012546239A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013515490A (ja
Filing date
Publication date
Priority claimed from PCT/US2010/041792 external-priority patent/WO2011008735A1/en
Application filed filed Critical
Priority claimed from PCT/US2010/062034 external-priority patent/WO2011079282A1/en
Publication of JP2013515490A publication Critical patent/JP2013515490A/ja
Publication of JP2013515490A5 publication Critical patent/JP2013515490A5/ja
Pending legal-status Critical Current

Links

JP2012546239A 2009-12-23 2010-12-23 組み換え型乳酸連鎖球菌のミニカプセルの経口投与による免疫保護 Pending JP2013515490A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28966309P 2009-12-23 2009-12-23
US61/289,663 2009-12-23
PCT/US2010/041792 WO2011008735A1 (en) 2009-07-13 2010-07-13 Oral vaccines produced and administered using edible micro-organism
USPCT/US2010/041792 2010-07-13
PCT/US2010/062034 WO2011079282A1 (en) 2009-12-23 2010-12-23 Immunoprotection by oral administration of recombinant lactococcus lactis mini-capsules

Publications (2)

Publication Number Publication Date
JP2013515490A JP2013515490A (ja) 2013-05-09
JP2013515490A5 true JP2013515490A5 (enExample) 2014-02-06

Family

ID=44196157

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012546239A Pending JP2013515490A (ja) 2009-12-23 2010-12-23 組み換え型乳酸連鎖球菌のミニカプセルの経口投与による免疫保護

Country Status (4)

Country Link
EP (1) EP2515661A4 (enExample)
JP (1) JP2013515490A (enExample)
CN (1) CN102665422B (enExample)
WO (1) WO2011079282A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2897638A1 (en) 2012-09-24 2015-07-29 Montana State University-Bozeman Recombinant lactococcus lactis expressing escherichia coli colonization factor antigen i (cfa/i) fimbriae and their methods of use
CN102965388A (zh) * 2012-12-07 2013-03-13 山东信得科技股份有限公司 一种表达猪传染性胃肠炎病毒基因工程菌制备方法
WO2015156419A1 (en) 2014-04-10 2015-10-15 Riken Compositions and methods for induction of th17 cells
CN104587458B (zh) * 2014-12-04 2017-01-04 吉林医药学院 预防贾第虫病的二价dna疫苗及其肠溶制剂
CN110511399B (zh) * 2019-07-26 2022-03-04 广西大学 一种控释型纳米纤维素抗菌微凝胶的制备方法
KR102254310B1 (ko) * 2019-10-02 2021-05-21 주식회사 고바이오랩 락토바실러스 애시도필러스 kbl409 균주 및 그 용도
CN116083240B (zh) * 2023-04-07 2023-08-29 深圳市第二人民医院(深圳市转化医学研究院) 工程化细菌及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0628083A1 (en) * 1992-02-27 1994-12-14 Microbial Technics Limited Heterologous gene expression in lactococcus, and the expression products therefrom
CN1120310A (zh) * 1993-03-11 1996-04-10 塞科雷泰克公司 在粘膜表面转运免疫原的聚合粘膜粘合剂
US6328967B1 (en) * 1998-03-12 2001-12-11 Allergenics, Inc. Delivery system to modulate immune response
EP1154793B1 (en) * 1999-02-26 2010-09-15 Novartis Vaccines and Diagnostics, Inc. Use of bioadhesives and adjuvants for the mucosal delivery of antigens
US8168228B2 (en) * 2003-10-17 2012-05-01 Sandoz Ag Antibiotic clarithromycin micropellet compositions
CN1997352B (zh) * 2004-06-17 2010-12-01 天野酶制品美国有限公司 含粘膜粘附性聚合物的酶、微生物和抗体的控释制剂
JP2009535306A (ja) * 2006-04-21 2009-10-01 ダウ・アグロサイエンス・エル・エル・シー 鳥インフルエンザに対するワクチンおよび使用方法
US20090324638A1 (en) * 2006-06-12 2009-12-31 Biopeptides Corp. Live bacterial vaccine
DK3354276T3 (da) * 2007-11-13 2020-03-30 Meritage Pharma Inc Sammensætninger til behandlingen af gastrointestinal inflammation

Similar Documents

Publication Publication Date Title
Grant et al. Human influenza viruses and CD8+ T cell responses
Altenburg et al. Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases
Belser et al. Influenza A virus transmission: contributing factors and clinical implications
JP2014507482A5 (enExample)
JP2013216685A5 (enExample)
JP2016539946A5 (enExample)
JP2016534034A5 (enExample)
JP2012126742A5 (enExample)
JP2012176990A5 (enExample)
CN109563492A (zh) 突变的病毒、其制备方法和应用
Dong et al. Incorporation of CD40 ligand or granulocyte-macrophage colony stimulating factor into Hantaan virus (HTNV) virus-like particles significantly enhances the long-term immunity potency against HTNV infection
JP2009535306A5 (enExample)
Banner et al. The current state of H5N1 vaccines and the use of the ferret model for influenza therapeutic and prophylactic development
ES2510940R1 (es) Composición farmacéutica combinada y su uso para preparar un medicamento destinado al tratamiento y prevención de las enfermedades infecciosas
CN104232594B (zh) 重组类禽型h1n1流感病毒灭活疫苗株(js40/pr8)及其制备方法和应用
Peng et al. Boosted influenza-specific T cell responses after H5N1 pandemic live attenuated influenza virus vaccination
JP2014511856A5 (enExample)
Avanthay et al. NS1 and PA-X of H1N1/09 influenza virus act in a concerted manner to manipulate the innate immune response of porcine respiratory epithelial cells
Zhang et al. Oral or intranasal immunization with recombinant Lactobacillus plantarum displaying head domain of Swine Influenza A virus hemagglutinin protects mice from H1N1 virus
JP2010506926A5 (enExample)
HRP20171697T1 (hr) Varijanta hiv gp-120
JP2014502143A5 (enExample)
BR112013000996A2 (pt) proteína l1 hpv58 truncada ou variante da mesma, ácido nucleíco isolado, vetor, célula hospedeira, partícula do tipo viral hpv58, composição, composição farmacêutica ou vacina, método para obter uma proteína l1 hpv58 truncada, método para preparar a partícula do tipo viral hpv58, método para preparar uma vacina, método para prevenir a infecção hpv ou uma doença causada por infecção hpv, e uso da proteína l1 hpv58 truncada ou variante da mesma
JP2016529316A5 (enExample)
Gao et al. It is not just AIV: from avian to swine-origin influenza virus